Clinical trialNCT01664637TerminatedPhase 2Interventional

Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

SponsorTranzyme, Inc.Enrollment120Diabetic Gastroparesis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered for 12 weeks, in diabetic subjects with symptoms associated with gastroparesis.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Elsa Mondou, M.D.
Tranzyme, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Poland

Tranzyme Investigational Site
Bialystok, Poland
Tranzyme Investigational Site
Bialystok, Poland
Tranzyme Investigational Site
Bydgoszcz, Poland
Tranzyme Investigational Site
Kielce, Poland
Tranzyme Investigational Site
Krakow, Poland
Tranzyme Investigational Site
Lodz, Poland
Tranzyme Investigational Site
Lublin, Poland
Tranzyme Investigational Site
Lublin, Poland
Tranzyme Investigational Site
Olsztyn, Poland
Tranzyme Investigational Site
Rzeszów, Poland
Tranzyme Investigational Site
Warsaw, Poland
Tranzyme Investigational Site
Zgierz, Poland

United States

Tranzyme Investigational Site
Huntsville, Alabama, United States
Tranzyme Investigational Site
Tucson, Arizona, United States
Tranzyme Investigational Site
North Little Rock, Arkansas, United States
Tranzyme Investigational Site
Long Beach, California, United States
Tranzyme Investigational Site
Ventura, California, United States
Tranzyme Investigational Site
Hialeah, Florida, United States
Tranzyme Investigational Site
Inverness, Florida, United States
Tranzyme Investigational Site
Jacksonville, Florida, United States
Tranzyme Investigational Site
Miami, Florida, United States
Tranzyme Investigational Site
Miami, Florida, United States
Tranzyme Investigational Site
New Smyrna Beach, Florida, United States
Tranzyme Investigational Site
Anderson, Indiana, United States
Tranzyme Investigational Site
Indianapolis, Indiana, United States
Tranzyme Investigational Site
Kansas City, Kansas, United States
Tranzyme Investigational Site
Monroe, Louisiana, United States
Tranzyme Investigational Site
Boston, Massachusetts, United States
Tranzyme Investigational Site
Mexico, Missouri, United States
Tranzyme Investigational Site
Raleigh, North Carolina, United States
Tranzyme Investigational Site
Salisbury, North Carolina, United States
Tranzyme Investigational Site
Winston-Salem, North Carolina, United States
Tranzyme Investigational Site
Oklahoma City, Oklahoma, United States
Tranzyme Investigational Site
Portland, Oregon, United States
Tranzyme Investigational Site
El Paso, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

10 mg TZP-102Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2012
Primary completion: 31 Jan 2013
Completion: 28 Feb 2013
Last update posted: 20 Dec 2012
Registered enrollment: 120
Registry id: NCT01664637

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.